// App-Quantinova.ai

3480 : Eculizumab Protects Against TE and Prolongs Survival in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Study

Researchers

Presenter

  • Hubert Schrezenmeier

Principal Investigators

  • Petra Muus

  • Gus Khursigara

  • Camille L. Bedrosian

  • Peter Hillmen

  • Jeffrey Szer

  • Alvaro Urbano-Ispizua

  • Jaroslaw P. Maciejewski

  • Robert A. Brodsky

  • Monica Bessler

  • Yuzuru Kanakura

  • Wendell F. Rosse

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Clinical Hematology & BMT, Royal Melbourne Hospital, Parkville, Australia

  • Grupo de Trabajo de HPN de la Sociedad Espanola de Hematologia y Hemoterapia, Barcelona, Spain

  • Radboud University Medical Center, Njmegen, Netherlands

  • Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan

  • Institute of Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service and Institute of Transfusion Medicine, University of Ulm, Ulm, Germany

  • Department of Hematology/Transplantation, Hopital Saint-Louis and Institut National de la Sante et de la Recherche Medicale INSERM, Paris, France

Locations

  • Japan

  • Netherlands

  • Spain

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Alexion Pharmaceutic

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Aplastic anemia

  • Venous thrombosis

  • Dyspnea

  • Anemia

Biomarkers

  • Lactate dehydrogenase

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • Red Blood Cells

Drug/Treatment

  • Eculizumab

  • Warfarin

  • Heparin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved